pp-045 Solution for infusion
Dossier type
CTD
Dossier status
Under development
Country of origin
South Korea
Comments
Indication: Solid tumors with ERBB3 (HER3) pathway involvement; evaluated in advanced/metastatic cancers.
Clinical stage: Phase 1 ( in the USA).
Modality: Biologic (humanized monoclonal antibody).
Mechanism / Target: Anti-ERBB3 (HER3) IgG1 mAb, designed to block neuregulin-ERBB3 signaling that drives tumor growth, survival, and resistance to EGFR/ERBB-targeted therapies.
Route / form: Intravenous infusion.
Differentiation: Targets HER3—a validated resistance node in EGFR, HER2, and PI3K-driven cancers—making it a complementary candidate for combination development.
Manufacturer #16907
This South Korea–based life-sciences organization develops a portfolio of small-molecule and biologic therapeutics, with a strategic focus on oncology, immunology, and metabolic diseases. Its pharmaceutical R&D is supported by global clinical programs and collaborations aimed at advancing first-in-class and best-in-class candidates. The group also maintains established therapeutic franchises and leverages international partnerships to expand its presence in the global healthcare market.
Manufacturer usually replies in 53 days